Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12285MR)

This product GTTS-WQ12285MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12285MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7733MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ8489MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ4454MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ1635MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ14949MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ6610MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ5955MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ1712MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW